These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30418193)

  • 1. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
    Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
    Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation: Erratum.
    Anticancer Drugs; 2024 Apr; 35(4):383. PubMed ID: 38451676
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
    Chakraborty JB; Mahato SK; Joshi K; Shinde V; Rakshit S; Biswas N; Choudhury Mukherjee I; Mandal L; Ganguly D; Chowdhury AA; Chaudhuri J; Paul K; Pal BC; Vinayagam J; Pal C; Manna A; Jaisankar P; Chaudhuri U; Konar A; Roy S; Bandyopadhyay S
    Cancer Sci; 2012 Jan; 103(1):88-99. PubMed ID: 21943109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H
    Paul T; Roy R; Sarkar RD; Sinha S; Biswas N
    Free Radic Biol Med; 2021 Apr; 166():265-276. PubMed ID: 33631302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
    Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
    Acharya S; Sahoo SK
    J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic apoptosis of CML cells by buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS pathway.
    Chowdhury AA; Chaudhuri J; Biswas N; Manna A; Chatterjee S; Mahato SK; Chaudhuri U; Jaisankar P; Bandyopadhyay S
    PLoS One; 2013; 8(9):e73672. PubMed ID: 24040019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Concern: Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
    Cancer Sci; 2024 Jun; 115(6):2086. PubMed ID: 38538295
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
    Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
    Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
    Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
    Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
    Trivedi R; Maurya R; Mishra DP
    Cell Death Dis; 2014 Oct; 5(10):e1465. PubMed ID: 25321472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.
    Seca H; Lima RT; Guimarães JE; Helena Vasconcelos M
    Hematology; 2011 Mar; 16(2):100-8. PubMed ID: 21418741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
    Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S
    Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.